We further treated mgR mice with Itgb1 mAb for 8 weeks, from 4 to 12 weeks of age (Figure 7B), and analyzed a unique chimeric integrin mouse model where the α5 integrin (Itga5) cytoplasmic domain is replaced with that of α2 integrin, resulting in resistance to atherosclerosis and decreased inflammatory activation (18). This evidence concerns the gene ITGB1 and atherosclerosis.